The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / FDA Approves Oral Methotrexate; Plus Restrictions for 2 Analgesics in Children

FDA Approves Oral Methotrexate; Plus Restrictions for 2 Analgesics in Children

May 16, 2017 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

The U.S. Food and Drug Administration (FDA) has approved a new formulation of methotrexate designed as an oral solution for pediatric patients. Also, the agency recently introduced age restrictions for codeine and tramadol for children under age 12, citing their risks for slowed or difficult breathing and death.

You Might Also Like
  • FDA Warns ‘Don’t Use Tramadol in Children’ & More
  • FDA Approves Drug to Counter Opioid ODs
  • Pacira Sues FDA over Pain Drug Marketing Restrictions
Also By This Author
  • Phase 3 Results for Olokizumab in RA Patients

FDA Approves Oral Methotrexate
Methotrexate (Xatmep), a folate analog metabolic inhibitor, is now available as an oral solution at a concentration of 2.5 mg/mL. This solution is a ready-to-use product designed to improve the accuracy of dosing and dispensing by eliminating the need for tablet crushing or extemporaneous compounding for pediatric dosing. This new formulation limits the risk of inadvertent methotrexate exposure and saves time. The medication requires refrigeration, but may be stored at room temperature for up to 60 days after dispensing.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The formulation was approved for managing pediatric patients with active polyarticular juvenile idiopathic arthritis who have had an insufficient therapeutic response to or are intolerant of an adequate trial of first-line therapy, such as full-dose non-steroidal anti-inflammatory drugs. It can also be used to treat pediatric patients with acute lymphoblastic leukemia as part of a multi-phase, combination chemotherapy maintenance regimen.

Analgesic Contraindications for Children & Nursing Mothers
The FDA has restricted the use of codeine and tramadol in children.2 Both codeine, which is approved for pain and cough, and tramadol, which is approved for pain, carry serious risks, including slowed or difficult breathing and death, which appear to be greater in children under 12 years of age. These drugs should not be used in patients of this age group. Additionally, the use of codeine and tramadol should be limited in some older children. All tramadol-containing products and single-ingredient codeine products are FDA approved for use only in adults.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

New labeling: The FDA will add a warning that recommends breastfeeding mothers refrain from using tramadol and codeine due to potential harm to their infants. Nursing infants whose mothers are taking these medications are at risk for excessive sleepiness, difficulty breastfeeding and serious breathing problems that may result in death. Tramadol is now contraindicated for use in children younger than 12 years old. A new contraindication was added to the tramadol label, warning against using it in children younger than 18 years old for post-operative pain from tonsillectomy and/or adenoid removal. Also, new label warnings for both codeine and tramadol advise against their use in children 12–18 years old who are obese, have severe lung disease or have obstructive sleep apnea, due to the increased risks for serious breathing trouble.

Pages: 1 2 | Single Page

Filed Under: Analgesics, DMARDs & Immunosuppressives, Drug Updates Tagged With: breastfeeding, codeine, FDA, Food and Drug Administration, infants, Methotrexate, Pediatric, tramadol

You Might Also Like:
  • FDA Warns ‘Don’t Use Tramadol in Children’ & More
  • FDA Approves Drug to Counter Opioid ODs
  • Pacira Sues FDA over Pain Drug Marketing Restrictions
  • Opioids More Dangerous than other Analgesics for Elderly

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.